CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lambert, W.
Right arrow Articles by Rowe, B. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lambert, W.
Right arrow Articles by Rowe, B. H.

Canadian Journal of Anesthesia, Vol 45, 571-574, Copyright © 1998 by Canadian Anesthesiologists' Society

ARTICLES

The effectiveness of low dose tranexamic acid in primary cardiac surgery

W Lambert, FJ Brisebois, TJ Wharton, RC Carrier, D Boyle and BH Rowe
Sudbury Memorial Hospital, Department of Anesthesiology, University of Alberta, Edmonton, Alberta.

PURPOSE: This randomized controlled clinical trial compared three doses of tranexamic acid (TA) in primary cardiac surgery in terms of blood loss and transfusion requirements. METHODS: Patients presenting for primary coronary artery bypass grafting (CABG) and/or valve replacement were randomly assigned to one of three TA regimens: 20 mg.kg-1 (LD), 50 mg.kg-1 (MD), and 100 mg.kg-1 (HD). All participants and staff were blinded to the allocation. Haemoglobin (Hgb), haematocrit and platelet count were determined preoperatively, after bypass, at CCA arrival, and 12 and 24 hr after surgery. Coagulation parameters were measured before and after surgery. Blood loss was measured intraoperatively and for 24 hr postoperatively following a standardized protocol. Blood products were administered in a standardized fashion. RESULTS: Two hundred twenty patients completed the trial over 10 months: 74 in LD, 75 in MD and 72 in HD dose groups. All patients groups were comparable; similar procedures were performed in each group. No differences were identified for blood loss intra-operatively (490 +/- 232 ml, 523 +/- 413 ml, 488 +/- 357 ml, respectively), 24 hr post-operatively (543 +/- 223 ml, 544 +/- 231, 458 +/- 210 ml, respectively), and overall (1032 +/- 358 ml, 1067 +/- 502 ml, 946 +/- 459 ml, respectively). Blood product administration was similar in the three groups. No differences in postoperative complications were found. CONCLUSIONS: This study demonstrates the equivalency of the three doses of TA in primary cardiac surgical procedures. The use of low dose (20 mg.kg-1) TA results in comparable outcomes, without additional complications.


This article has been cited by other articles:


Home page
 ICVTSHome page
S. Thiagarajamurthy, A. Levine, and J. Dunning
Does prophylactic tranexamic acid safely reduce bleeding without increasing thrombotic complications in patients undergoing cardiac surgery?
Interactive CardioVascular and Thoracic Surgery, September 1, 2004; 3(3): 489 - 494.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. A. Ruel, F. Wang, M. E. Bourke, J.-Y. Dupuis, J. A. Robblee, W. J. Keon, and F. D. Rubens
Is tranexamic acid safe in patients undergoing coronary endarterectomy?
Ann. Thorac. Surg., May 1, 2001; 71(5): 1508 - 1511.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the Canadian Anesthesiologists' Society.